Cogent Biosciences, Inc. COGT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$97.35M-35.2% | -$102.49M-50.9% | -$80.93M-14.6% | -$73.53M-24.7% | -$71.99M-23.4% | ||
| $626K-2.2% | $628K+0.5% | $641K+3.4% | $655K+8.1% | $640K+6.8% | ||
| $16.91M+68.9% | $15.75M+57.9% | $10.6M+2.4% | $9.72M-3.0% | $10.01M+6.5% | ||
| $278K— | $238K— | $300K— | $63K— | $0— | ||
| -$135K— | —— | —— | —— | -$0— | ||
| $4.24M+98.0% | -$6.53M— | -$596K-110% | $2.47M+137% | $2.14M-56.4% | ||
| -$10.2M-17.8% | $9.1M+60.7% | $4.57M-34.0% | $5.68M-43.8% | -$8.66M-28.8% | ||
| $1.84M+184% | $3.24M-4.4% | -$806K— | -$63K-111% | -$2.17M-297% | ||
| $29K+480% | $13K— | $11K— | $4K— | $5K— | ||
| $529K+6.2% | $513K+6.2% | $506K+6.1% | $502K+5.9% | $498K+6.6% | ||
| —— | -$1.8M— | -$1.8M— | -$1.8M— | -$1.8M— | ||
| -$86.88M-30.6% | -$79.11M-30.6% | -$64.29M-23.7% | -$54.54M-27.7% | -$66.51M-26.6% | ||
| $449K-17.9% | $811K+981% | $65K-76.8% | $131K-11.5% | $547K+681% | ||
| -$36.46M-153% | -$322.77M-623% | -$155.05M-358% | $8.91M+111% | $69.38M+6,545% | ||
| —— | $13.66M— | $13.66M— | $13.66M— | $13.66M— | ||
| $5.76M+4,132% | $10.36M— | $1.04M— | $5K— | $136K— | ||
| —— | $12.22M— | $12.22M— | $12.22M— | $12.22M— | ||
| $52.54M+110% | $588.67M+2,264,012% | $217.37M+34,734% | $47.23M— | $24.97M-88.3% | ||
| -$70.8M-354% | $186.8M+16,578% | $0-100% | $1.6M— | $27.84M-82.9% | ||
| $1.18M+23.6% | $1.06M-59.4% | $167K-97.3% | —— | $955K-31.6% | ||
| $278K— | $238K— | $300K— | $63K— | $0— | ||
| —— | $641K+4.7% | $641K+4.7% | $641K+4.7% | $641K+4.7% | ||
| -$10.2M-17.8% | $9.1M+60.7% | $4.57M-34.0% | $5.68M-43.8% | -$8.66M-28.8% | ||
| -$422K-12.2% | -$407K-12.4% | -$400K-12.7% | -$382K-12.7% | -$376K-13.9% | ||
| -$1.36M— | -$1.19M-29,575% | -$374K— | $0— | -$0-100% | ||
| $1.84M+184% | $3.24M-4.4% | -$806K— | -$63K-111% | -$2.17M-297% | ||
| $529K+6.2% | $513K+6.2% | $506K+6.1% | $502K+5.9% | $498K+6.6% | ||
| —— | $55.78M— | $55.78M— | $55.78M— | $55.78M— | ||
| $1.06M+81.8% | —— | $766K+36.5% | —— | $584K+64.0% | ||
| $45.71M+88.5% | $135.07M— | —— | —— | $24.25M— | ||
| —— | $13.66M— | $13.66M— | $13.66M— | $13.66M— | ||
| —— | —— | —— | —— | —— | ||
| $152K+92.4% | —— | —— | —— | $79K— | ||
| -$87.33M-30.2% | -$79.92M-31.8% | -$64.35M-23.1% | -$54.67M-27.6% | -$67.06M-27.5% | ||
| -$87.33M-30.2% | -$79.92M-31.8% | -$64.35M-23.1% | -$54.67M-27.6% | -$67.06M-27.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cogent Biosciences, Inc. generate?
- Cogent Biosciences, Inc. (COGT) generated -$284.8M in operating cash flow over the trailing twelve months.
- What is Cogent Biosciences, Inc.'s free cash flow?
- After $1.5M of capital expenditures, Cogent Biosciences, Inc.'s free cash flow was -$286.3M over the trailing twelve months, down 28.5% year over year.
- Where does Cogent Biosciences, Inc.'s cash flow data come from?
- Every line is extracted from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
